To present a case of a patient with metastatic pancreatic cancer who developed fatal pneumonitis following treatment with Camrelizumab, Erlotinib, and chemotherapy, highlighting the risks associated with this combination.
Key Findings:
The patient was diagnosed with metastatic pancreatic cancer after presenting with abdominal pain and a subcutaneous lesion.
Initial treatment with nab-paclitaxel and gemcitabine was ineffective, leading to a switch to FOLFIRI combined with Camrelizumab and Erlotinib.
The patient experienced fatal pneumonitis, underscoring the potential risks associated with combining immunotherapy and targeted therapy.
Interpretation:
This case suggests that the combination of Camrelizumab and Erlotinib may pose significant risks, including severe pneumonitis, in patients with advanced pancreatic cancer, warranting careful consideration in treatment planning.
Limitations:
This is a single case study, limiting the generalizability of the findings.
No comparative data on the safety of Camrelizumab and Erlotinib in a larger cohort, and potential biases in treatment response.
Conclusion:
The combination of immunotherapy and Erlotinib may not be a safe therapeutic strategy for advanced pancreatic cancer due to the risk of severe pneumonitis, emphasizing the need for vigilant monitoring.
